Navigation Links
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
Date:4/21/2009

by blocking the activity of at least three "inhibitors of apoptosis proteins" or IAPs (including XIAP, c-IAP1, and c-IAP2) to create conditions in which apoptosis can proceed. As such, AT-406 is considered a multi-IAP antagonist. IAPs are key components of the complex cascade of protein signaling that activates enzymes called caspases to initiate breakdown of the cancer cell. AT-406 is thought to mimic the activity of Smac (second mitochondria-derived activator of caspases) by binding to XIAP and preventing it from inhibiting caspase activation. Upon binding, AT-406 induces rapid degradation of cIAP-1/2 proteins and promotes apoptosis through activation of caspase-8 and the death-receptor complex.

AT-406 is in late-stage preclinical development and has demonstrated strong single-agent antitumor activity in multiple xenograft models of human cancer, including breast cancer, pancreatic cancer, prostate cancer, and lung cancer. AT-406 has also been shown to work synergistically with conventional chemotherapeutic and targeted agents (such as tyrosine kinase inhibitors) in preclinical tumor models.

Other Research Including AT-101

Ascenta Therapeutics also announced that researchers from the University of Pennsylvania presented results at AACR from an independent laboratory study examining the role of Bcl-2 homology (BH) family proteins in the development of chemotherapy resistance in neuroblastoma (Abstract # 3269). Using human-derived neuroblastoma cell lines, these investigators demonstrated differential resistance patterns to inhibitors of the Bcl-2 family proteins based on the relative BH proteins expressed (specifically, Mcl-1 or Bcl-2). They showed that Ascenta's small molecule pan-Bcl-2 inhibitor, AT-101, had preferential inhibition in Mcl-1 predominant lines. They concluded that compounds with activity against Mcl-1 may be useful in the treatment of high-risk neuroblastoma and warrant further stu
'/>"/>

SOURCE Ascenta Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
2. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
3. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
6. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
7. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
8. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
9. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
10. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
11. Arno Therapeutics Reports 2008 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... one of the most promising technologies for future quantum ... (photons) instead of electrons. First, it is necessary to ... and control their direction. Researchers around the world have ... but now scientists at the Niels Bohr Institute have ... one at a time and in a particular direction. ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... Research “Global Orthobiologics Market” the global orthobiologics market was valued ... reach a market worth USD 5,519.9million in 2019at a CAGR ... the population aged 50 years and above is afflicted by ... almost double by the year 2020. This has and will ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Three ... Energy's 2014 Hydrogen Production R&D Award ... by splitting water using sunlight. , Shared with ... and the University of Nevada, Las Vegas (UNLV), ... developing models of photoelectrochemical solar-hydrogen production and corrosion ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2
... INDIANAPOLIS, Sept. 23 The volume of biological samples ... pharmaceutical and biotechnology industries shift their focus from traditional ... and biomarkers in the discovery process has put an ... the practices that life sciences companies employ to collect, ...
... Pharmaceutical and Biotech Trainers (SPBT) today announced that Kevin ... October 1.  He brings to his new role significant ... Mr. Kruse will be responsible for leading ... organization that represents more than 1,000 members in the ...
... 23, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 2BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 3Kevin Kruse Named Executive Director of the Society of Pharmaceutical and Biotech Trainers 2BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 2BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 3BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 4BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 5BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 6BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 7
(Date:8/31/2014)... not busy attacking us, germs go after each other. ... disaster for the infected microbes: Sometimes viruses actually carry ... expand its diet or better attack its own hosts. ... immune system would robotically destroy anything it recognized as ... have now revealed that one variety of the bacterial ...
(Date:8/31/2014)... Climate Change , suggests that if current trends continue ... global targets for total greenhouse gas (GHG) emissions in 2050. ... carefully about the food we choose and its environmental impact. ... one of a number of actions that need to be ... enough food for all. , As populations rise and ...
(Date:8/31/2014)... in French . ... in the prestigious Nature Neuroscience journal by, Sylvain ... the Douglas Mental Health University Institute and McGill University, opens ... dynamic mechanisms controlling memory as well of the role of ... the subiculum. , In 2009, they developed a unique ...
Breaking Biology News(10 mins):Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2
... genome-wide association study published today in Nature Genetics ... in eight blood measurements and the impact those variants ... the number and volume of cells in the blood, ... disorders, including anaemia, infection and blood cell cancers. ...
... of human papillomavirus is seen across the population of India, ... vaccination targeting these types could eliminate 75 percent of the ... the American Association for Cancer Research Frontiers in Basic Cancer ... the most common cancer among Indian women, with an estimated ...
... across the Panama Canal in a Boston Whaler may sound ... of this story brandishes a butterfly net and studies the ... Tropical Research Institute. , "Our long-term study shows ... migrations," said Robert Srygley, former Smithsonian post doctoral fellow who ...
Cached Biology News:Blood counts are clues to human disease 2Blood counts are clues to human disease 3Scientists identify common HPV genotypes in northern India, encourage vaccination 2Panama butterfly migrations linked to El Nio, climate change 2
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
Biology Products: